<DOC>
	<DOC>NCT00869284</DOC>
	<brief_summary>Phase II multicenter pilot trial (073) evaluating tandem HDT with PBSC support in aa-IPI=3 untreated aggressive NHL.</brief_summary>
	<brief_title>Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's Lymphomas</brief_title>
	<detailed_description>High-dose chemotherapy; untreated aggressive non-Hodgkin's lymphoma; high-risk; peripheral blood stem cell support Patients were aged from 15 to 60 years</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<criteria>patients aged from 15 to 60 years previously untreated histologically proven aggressive NHL high aaIPI (equal to 3) proper underlying organ function transformed lowgrade, lymphoblastic, mantlecell, or Burkitt's lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>High-dose chemotherapy</keyword>
	<keyword>aggressive NHL</keyword>
	<keyword>high-risk</keyword>
	<keyword>PBSC</keyword>
</DOC>